1,924
+1.26%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About J Frontier Co
Its shares trade on Tokyo Stock Exchange under the ticker 2934.T. It has been listed since 27 August 2021. In the fiscal year to 31 May 2026, it reported revenue of ¥22.24bn and a net loss of ¥321.3m. At that date it held total assets of ¥9.59bn and shareholders' equity of ¥1.23bn.
J Frontier Co., Ltd. engages in the sale, manufacture, planning, and development of healthcare products. The company is headquartered in Shibuya-Ku, Tokyo-To. The company went IPO on 2021-08-27. The firm operates through three business segments. The Healthcare Sales segment is engaged in the planning and development of health foods and cosmetics represented by the 328 selection series of fermented hydrogen and mail-order sales. The Medical Care Sales segment is engaged in the operation of dispensing pharmacies, mail-order business of ethical drugs, as well as planning, development and mail-order sales of drugs such as Why Pure series and Chinese herbs. The Health Care Marketing segment is mainly engaged in advertising agency business related to health care products, sales promotion support for health care products, as well as wholesale of in-house products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 27 Aug 2021
- Employees
- 255
- Website
- jfrontier.jp ↗
Leadership
Pay as last reported
- Mr. Atsuhiro NakamuraExecutive President, Representative Director, since 2021
- Mr. Yuya HiguchiExecutive Officer, Chief Financial Officer, Chief Director of Business Planning, Director, since 2024
- Mr. Satoshi KambeChief Operating Officer, Executive Officer, Chief Director of Health Care Sales Business, Director, since 2022
- Ms. Sumiko OkamotoExecutive Officer, Chief Director of Corporate
- Ms. Nana FukasawaExecutive Officer, Chief Director of SOKUYAKU Business
- Mr. Tsutomu AkitaIndependent Director
- Mr. Kazuki FurukawaIndependent Director
- Mr. Akitoshi ImamuraIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- J Frontier's Healthcare Sales segment offers 328 fermented hydrogen health food products with mail-order sales.
- The Medical Care Sales segment operates dispensing pharmacies and ethical drug mail-order services.
- Health Care Marketing segment provides advertising and sales promotion for health care products.
Weaknesses
- J Frontier has only 255 employees, which may limit operational capacity.
- The company's IPO was in 2021, indicating a relatively new market presence.
- Limited business segments with only three operational divisions.
Opportunities
- Expanding the 328 fermented hydrogen product line into new markets.
- Increasing mail-order sales for ethical drugs in the Medical Care Sales segment.
- Growing the Health Care Marketing segment through digital advertising channels.
Threats
- Competition from established health food brands in Japan.
- Regulatory changes affecting pharmaceutical mail-order services.
- Economic downturns impacting consumer spending on health products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.